99 related articles for article (PubMed ID: 1450185)
21. Repeat length variation in the dopamine D4 receptor gene shows no evidence of association with schizophrenia.
Daniels J; Williams J; Mant R; Asherson P; McGuffin P; Owen MJ
Am J Med Genet; 1994 Sep; 54(3):256-8. PubMed ID: 7810584
[TBL] [Abstract][Full Text] [Related]
22. Are there neurochemical indicators of risk for schizophrenia?
Csernansky JG; Newcomer JW
Schizophr Bull; 1994; 20(1):75-88. PubMed ID: 7910978
[TBL] [Abstract][Full Text] [Related]
23. Unitary models of schizophrenia.
Br J Psychiatry; 1989 Mar; 154():414-8. PubMed ID: 2557108
[No Abstract] [Full Text] [Related]
24. [Psychopharmacologic approaches to schizophrenic psychoses].
Giacardy-Paty M; Soubrouillard C; Blin O
Encephale; 1995 Jun; 21 Spec No 3():3-8. PubMed ID: 7628339
[TBL] [Abstract][Full Text] [Related]
25. The dynamics of complex biological psychosocial systems. Four fundamental psycho-biological mediators in the long-term evolution of schizophrenia.
Ciompi L
Br J Psychiatry Suppl; 1989 Jul; (5):15-21. PubMed ID: 2690886
[No Abstract] [Full Text] [Related]
26. Neuroleptic-induced supersensitivity psychosis: retrospective study of schizophrenic inpatients.
Hunt JI; Singh H; Simpson GM
J Clin Psychiatry; 1988 Jul; 49(7):258-61. PubMed ID: 2899071
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneity of dopamine receptors.
Jarvie KR; Caron MG
Adv Neurol; 1993; 60():325-33. PubMed ID: 8380525
[No Abstract] [Full Text] [Related]
28. The dopamine hypothesis: variations on a theme (II).
Wyatt RJ
Psychopharmacol Bull; 1986; 22(3):923-7. PubMed ID: 3797593
[No Abstract] [Full Text] [Related]
29. The neurobiology of cognition in schizophrenia.
Tamminga CA
J Clin Psychiatry; 2006 Sep; 67(9):e11. PubMed ID: 17081078
[TBL] [Abstract][Full Text] [Related]
30. [Biological markers in schizophrenia].
Lembreghts M; Ansseau M
Encephale; 1993; 19(5):501-23. PubMed ID: 8306920
[TBL] [Abstract][Full Text] [Related]
31. [Sex differences in schizophrenia].
Häfner H; Gattaz WF
Gynakologe; 1995 Dec; 28(6):426-33. PubMed ID: 8566873
[No Abstract] [Full Text] [Related]
32. [Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia].
Guise S; Soubrouillard C; Blin O
Encephale; 1997 Apr; 23 Spec No 2():10-6. PubMed ID: 9273300
[TBL] [Abstract][Full Text] [Related]
33. Is there a right hemi-hyper-dopaminergic psychosis?
Bracha HS
Schizophr Res; 1989; 2(4-5):317-24. PubMed ID: 2487172
[TBL] [Abstract][Full Text] [Related]
34. New antipsychotic agents and the future.
Mackay AV
J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):51-3. PubMed ID: 2858482
[TBL] [Abstract][Full Text] [Related]
35. No association between schizophrenia and homozygosity at the D3 dopamine receptor gene.
Yang L; Li T; Wiese C; Lannfelt L; Sokoloff P; Xu CT; Zeng Z; Schwartz JC; Liu X; Moises HW
Am J Med Genet; 1993 Jul; 48(2):83-6. PubMed ID: 8103292
[TBL] [Abstract][Full Text] [Related]
36. Current concepts in schizophrenia: international symposia report new standards for assessment and treatment. Part I: Pathophysiology research prompts assessment updates.
J Clin Psychiatry; 1995 May; 56(5):214-25. PubMed ID: 7737963
[No Abstract] [Full Text] [Related]
37. Dopamine receptor hetero-oligomerization in the pathogenesis of schizophrenia: qualitative as opposed to quantitative notions of dopaminergic receptors.
Tsai SJ; Hong CJ
Schizophr Res; 2003 Sep; 63(1-2):197-8. PubMed ID: 12892875
[No Abstract] [Full Text] [Related]
38. Positive and negative syndromes in schizophrenia.
Tandon R; Greden JF
Am J Psychiatry; 1989 Mar; 146(3):407. PubMed ID: 2919706
[No Abstract] [Full Text] [Related]
39. A proposed neuroendocrine model of the schizophrenias.
Cowen MA; Green MR; Bertollo DN
Psychoneuroendocrinology; 1993; 18(8):v-x. PubMed ID: 8127944
[No Abstract] [Full Text] [Related]
40. Dopamine and schizophrenia.
More J
Hosp Community Psychiatry; 1991 Apr; 42(4):429. PubMed ID: 1888371
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
